Press ReleasesPoko Innovations, Inc. Receives Validation And Authorization To Sell...

Poko Innovations, Inc. Receives Validation And Authorization To Sell 44 Items In The UK

-

POKO Innovations an award-winning UK-based collection of CBD-focused companies that bring innovative, inspiring solutions to the CBD industry through the company’s leading platforms which, when working together, form a complete ecosystem, is pleased to announce today that it has received validation and authorization from the UK Food Standard Agency (FSA) under the Novel Food Application for 44 CBD products to be sold in the UK – any product not on the FSA approved list must be removed from sale.

The list was first published in April, 2021 and is updated periodically. Among the 44 approved CBD products are POKO Gummies, Oral Sprays, CBD C Coffee and Teas, Capsules and Tinctures; these 44 CBD products are listed under POKO subsidiaries Candid and Canmed Brands. POKO CBD Pouches were also approved.

“This is one of the most important events in the history of our young company and it enables Poko Innovations to complete discussions and negotiations with large retailers and wholesalers in the UK, Ireland and the EU,” said POKO CEO David Hughes.

“Up to this point in time we have been selling our products in test markets very successfully, and now, with this approval, we can approach any retailer or wholesaler in the UK,” said POKO COO Justine O’ Hanlon.

The company has also launched its Rob Kearney and Jess Redden social media campaign ahead the launch of its Rob Kearny-endorsed daily SPF 50 moisturizer.

Novel Foods are ingredients which have not been widely consumed by people in the UK or European Union before May 1997. With the FSA approval POKO can now aggressively market its products in the UK, Ireland and the EU.

According to industry data the CBD market in the UK comprises 8 percent of the adult population, representing sales of more than $250 million dollars and should be valued at $1.3 billion by 2025.

Latest news

MGC Pharmaceuticals Releases Update On CimetrA Clinical Trial Progress In USA

MGC Pharmaceuticals Ltd (ASX, LSE: MXC, ‘MGC Pharma’ or ‘the Company’), a European based bio-pharma company specialising in the production and development...

European Cannabis Stocks Review: Akanda’s ‘Concerned Shareholders’ Oust All Directors Except CEO To Prevent ‘Potentially Irreparable Harm’ – More From Goodbody Health & Chill...

It has been another week of positive developments for the cannabis industry across Europe, with yet more markets making...

Analysis Shows UK Market Could Grow To Over £1bn By 2026 As London Prepares To Host Europe’s Leading Cannabis Conference

ANALYSIS shows UK market could grow to over £1bn by 2026 as London prepares to host Europe’s leading cannabis...

Medical Cannabis Could Be Available In Spain By The End Of The Year

SPAIN could now see the regulation and distribution of medical cannabis rolled out before the end of the year...

New UK Company Heralds Its ‘Unique’ Medical Cannabis Delivery Mechanism

CANNABIS extraction and formulations specialist 113 Botanicals is in the process of securing Good manufacturing Practice (GMP) compliance for...

German Cannabis Bill By Year End With Adult-Use Launch Likely In Early 2024

GERMANY’s draft cannabis law should be ready by the end of the year with the launch of its adult-use...

Must read

You might also likeRELATED
Recommended to you